Viridian Therapeutics, Inc. (VRDN)
22.37
-0.45
(-1.97%)
USD |
NASDAQ |
Oct 23, 16:00
22.36
0.00 (0.00%)
After-Hours: 20:00
Viridian Therapeutics Enterprise Value : 1.893B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 1.893B |
| October 22, 2026 | 1.943B |
| October 21, 2026 | 1.965B |
| October 20, 2026 | 1.899B |
| October 19, 2026 | 1.715B |
| October 16, 2026 | 1.514B |
| October 15, 2026 | 1.574B |
| October 14, 2026 | 1.441B |
| October 13, 2026 | 1.423B |
| October 12, 2026 | 1.432B |
| October 09, 2026 | 1.472B |
| October 08, 2026 | 1.436B |
| October 07, 2026 | 1.429B |
| October 06, 2026 | 1.423B |
| October 05, 2026 | 1.511B |
| October 02, 2026 | 1.556B |
| October 01, 2026 | 1.510B |
| September 30, 2026 | 1.691B |
| September 29, 2026 | 1.624B |
| September 28, 2026 | 1.689B |
| September 25, 2026 | 1.677B |
| September 24, 2026 | 1.699B |
| September 23, 2026 | 1.786B |
| September 22, 2026 | 1.864B |
| September 21, 2026 | 1.803B |
| Date | Value |
|---|---|
| September 18, 2026 | 1.851B |
| September 17, 2026 | 1.843B |
| September 16, 2026 | 1.900B |
| September 15, 2026 | 1.831B |
| September 14, 2026 | 1.873B |
| September 11, 2026 | 1.765B |
| September 10, 2026 | 1.883B |
| September 09, 2026 | 1.933B |
| September 08, 2026 | 1.983B |
| September 04, 2026 | 1.955B |
| September 03, 2026 | 1.959B |
| September 02, 2026 | 1.939B |
| September 01, 2026 | 1.967B |
| August 31, 2026 | 1.982B |
| August 28, 2026 | 1.973B |
| August 27, 2026 | 2.064B |
| August 26, 2026 | 2.107B |
| August 25, 2026 | 2.097B |
| August 24, 2026 | 2.079B |
| August 21, 2026 | 2.110B |
| August 20, 2026 | 2.134B |
| August 19, 2026 | 2.168B |
| August 18, 2026 | 2.069B |
| August 17, 2026 | 1.974B |
| August 14, 2026 | 1.860B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vertex Pharmaceuticals, Inc. | 126.85B |
| TG Therapeutics, Inc. | 8.494B |
| Travere Therapeutics, Inc. | 4.844B |
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -127.12M |
| Revenue (Quarterly) | 0.284M |
| Total Expenses (Quarterly) | 127.40M |
| EPS Diluted (Quarterly) | -1.178 |
| Gross Profit Margin (Quarterly) | 58.80% |
| Profit Margin (Quarterly) | -44.76K% |
| Earnings Yield | -16.58% |
| Normalized Earnings Yield | -16.75 |